Measuring decline in progressive supranuclear palsy

Measuring decline in progressive supranuclear palsy

  • Longitudinal changes in tau positron emission tomography (tau-PET) using the radioligand [18F]AV-1451 did not correlate to changes in disease severity in progressive supranuclear palsy (PSP).

Why this matters

  • The poor longitudinal performance of [18F]AV-1451 tau-PET scan compared to traditional MRI measures of midbrain atrophy indicates that, at this time, the latter is a more appropriate assessment for longitudinal change in PSP clinical trials.